ArticleQatar medical journal2025
Assessment of the trends in lipoprotein(a) concentration in high-risk cardiovascular patients: A retrospective study.
Article in Qatar medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiovascular disease (CVD) affects 500 million people globally, with mortality over 20 million. In the UK, the financial burden is estimated to be approximately £54 billion. Consequently, Lp(a) has been incorporated as an additional biomarker for cardiovascular risk stratification. It is used as a superior marker over the traditional marker LDL-C. Methods: This was a single-centre retrospective study conducted at Hampshire Hospital NHS Foundation Trust spanning 16 months (September 2022-January 2024). Lp(a) results were retrieved from the laboratory database and assessed for trends. The distribution of Lp(a) results was also compared with the values outlined in the HEART UK consensus statement (2019). Additionally, demographic characteristics such as age, sex, medical history, and lifestyle factors were collected. Personal details, including names, addresses, and phone numbers, were anonymised to ensure confidentiality. A total of 192 patients were included in the study. These patients were referred for a lipid panel by lipid specialists (172), GP surgeries (10), cardiologists (5), unspecified consultants (3) and endocrinologists (2). All patients were over 18 years of age. They were attending the clinic and had been screened for dyslipidaemia and high cardiovascular risk, including conditions such as familial hypercholesterolaemia, renal dysfunction, and those on antilipid therapy. Results: The demography included 99 (52%) females and 93 (48%) males. The chronological age (mean ± SD) was 61.17 ± 13.18 for females and 53.91 ± 12.84 for males ( Conclusion: This study provided evidence supporting the inclusion of Lp(a) as an extra component in lipid profile testing. Elevated levels of Lp(a) are associated with an increased risk of CVD, which may be more significant than the risk posed by LDL-C. Incorporating Lp(a) as a routine biomarker in real-world clinical practice would accurately stratify cardiovascular risk, particularly for patients with elevated Lp(a) concentrations, and could potentially be a more significant risk than LDL-C in individuals at high risk for CVD, especially for those ≥ 50 years of age.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.